US Stocks Drift Higher as Traders Eye US-China Trade Talks
US stocks crept higher on Tuesday as the US and China resumed their tariff talks for a second day in London, with financial markets on edge as the world's two largest economies try to avoid escalating the ongoing trade war further.
The S&P 500 Index rose 0.2% as of 9:35 a.m. in New York, leaving the equities benchmark less than 2.2% from its record after closing above the psychologically important 6,000 level for two straight sessions for the first time since mid-February. The Nasdaq 100 Index, which sits within 1.7% of its peak, inched up 0.1%. A basket tracking so-called Magnificent Seven stocks including Nvidia Corp., Alphabet Inc. and Meta Platforms Inc. rose 1%, with Tesla Inc. the best performer of the cohort.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
7 minutes ago
- Bloomberg
The Deal: Magic Johnson
In this episode of The Deal, Alex Rodriguez and Jason Kelly talk with Magic Johnson, the iconic point guard for the Los Angeles Lakers. In their conversation, taped in front of a live audience at the Milken Global Conference, Johnson reveals what he's learned from his 'greatest deal,' becoming part of the Washington Commanders ownership group. He also explains why pitching himself as a partner to the Starbucks board was the hardest thing he's ever done, and how much it meant to win an Olympic gold medal alongside Michael Jordan and Larry Bird.
Yahoo
9 minutes ago
- Yahoo
States sue to block the sale of genetic data collected by DNA testing company 23andMe
Dozens of states have filed a joint lawsuit against the bankrupt DNA-testing company 23andMe to block the company's sale of its customers' genetic data without explicit consent. The suit, filed this week in U.S. Bankruptcy Court in the Eastern District of Missouri, comes months after 23andMe began a court-supervised sale process of its assets. The South San Francisco-based venture was once valued at $6 billion and has collected DNA samples from more than 15 million customers. The company's bankruptcy has raised questions over privacy standards for genetic data, which experts say is uniquely sensitive, immutable and irreplaceable if stolen. Twenty-seven states and the District of Columbia filed the lawsuit, arguing that 23andMe customers have an inherent right to their own genetic information. Read more: 'People should be worried': 23andMe bankruptcy could expose customers' genetic data 'This isn't just data — it's your DNA," said Oregon Atty. Gen. Dan Rayfield in a statement. "It's personal, permanent, and deeply private. People did not submit their personal data to 23andMe thinking their genetic blueprint would later be sold off to the highest bidder." 23andMe announced in May that it would be sold to New York-based drug maker Regeneron Pharmaceuticals, which had agreed to comply with 23andMe's existing privacy policy. However, a competing offer from nonprofit TTAM Research Institute led the bankruptcy judge to reopen the auction last week. TTAM is run by 23andMe co-founder Anne Wojcicki, who has made several failed attempts to take the company private. In a statement, a 23andMe spokesperson said the lawsuit's claims "are without merit" and that the sale of genetic data does not violate privacy regulations. 'Customers will continue to have the same rights and protections in the hands of the winning bidder," the spokesperson said. Read more: Congressmen sound alarm over data privacy following 23andMe bankruptcy 23andMe customers have the right to delete their genetic information from the company's database at any time, as outlined in the Genetic Information Privacy Act and the California Consumer Privacy Act. During a testimony in Washington earlier this week, 23andMe interim Chief Executive Joseph Selsavage said that 1.9 million customers have requested their data be deleted since the company's bankruptcy filing in March. Sara Geoghegan, senior counsel at the Electronic Privacy Information Center, said that 23andMe's privacy policy was subject to change and not adequate to protect customers' data. In an interview in March, she stressed the sensitivity of genetic data. 'I would be very concerned if I had given a swab to 23andMe," she said. "There is little we can do to control what happens to it." Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights. This story originally appeared in Los Angeles Times.
Bloomberg
10 minutes ago
- Bloomberg
US Inflation Beats Estimates for a Fourth Month
For four months many economists have predicted that US inflation would reignite, in large part due to President Donald Trump's trade war and the knock-on effects his tariffs would have on the economy. But for a fourth month in a row, data released by the Trump administration's Bureau of Labor Statistics came in lower than expected. The consumer price index, excluding the often volatile food and energy categories, increased only 0.1% from April, according to government data. The string of below-forecast inflation readings could be attributable to how many of the administration's threatened levies are on hold. (In early April, Trump's 'reciprocal' tariffs managed to destabilize the bond market before he largely retreated.) Treasury Secretary Scott Bessent, who is being floated as a potential replacement for Jerome Powell at the Federal Reserve, credited Trump's trade policies for slowing inflation, saying he challenged a 'decades-old status quo.'
